Last Time … is not … This Time

The Rule of Alternation

That’s it in a nutshell. What happened last time, won’t happen this time.

The market reveals its own secrets; you just have to know where to look.

An entire industry has been (purposely) built to make sure the ‘average investor’ never finds the truth of the markets.

That industry is the financial analysis industry; the one with the P/E ratios, Debt-to-Equity, and so on.

Sure, it was a tongue-in-cheek post to use the fact that Carvana had no P/E (linked here).

I’m not certain if they ever had a P/E; probably not.

However, that financial, i.e., fundamental(s) fact, did not keep the stock from going up over 4,529%, in four years.

It should be noted, the Carvana analysis was done on a Saturday (as has this one). At the very next trading session, CVNA posted lower, started its decline in earnest and never looked back.

Not saying that exact thing (timing it to the day) will happen with our next candidate real estate; as said before, part of Wyckoff analysis (a lot of it, actually) is straight-up intuition.

The good part from a computer manipulated and controlled market perspective, intuition can’t be quantified.

So, that’s your edge.

Let’s move on to ‘last time is not this time’ and see what the real estate market IYR, is telling us.

Weekly Chart, IYR

We’ve got the weekly un-marked chart of IYR, below.

The ‘alternation’ is there.

Here it is, close-up.

The first leg lower had some initial smoothness but quickly became choppy and overlapping.

Not so, now.

We’re essentially heading straight down.

Fundamentals

From a fundamental standpoint, real estate is finished. However, it’s been finished for a long time.

The fundamentals won’t and can’t tell anyone what’s likely to happen at the next trading session … or any other session.

The market itself (shown above) is saying the probabilities are for a continued decline; posting smooth long bars until some meaningful demand is encountered.

As shown on the last post, if the trading channel is in-effect, that (chart) demand is a long way down.

Positioning

Shorting IYR via DRV, has been covered in previous posts (search for DRV-22-02).

The following weekly chart, is marked up with two arrows.

Arrow No. 1

Initial short position via DRV was opened late in the day on April 28th; the day before the market broke significantly lower (not advice, not a recommendation).

Arrow No. 2

As the market headed lower during the week just ended, the size of the DRV position was increased by 36%.

Currently, the gain on the total position is about +22%.

At this juncture, the DRV stop is located well in the green in the unlikely event we get a sharp IYR, upward move in the coming week.

Summary

Under ‘normal’ conditions one could expect some kind of upward bounce in the days ahead.

However, as shown already with big cap leader PLD, the situation’s anything but normal.

Highlighted in earlier posts, biotech is leading the way with SPBIO, currently down – 59.8%, from its highs.

Biotech IBB, with chief cook and (globalist) bottle washer Moderna (MRNA), is down – 36.2%.

As Dan from i-Allegedly has stated time and again, we’re already in a depression.

So, buckle your seatbelt Dorothy …

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

‘Heart Failure’ … The New Normal

… What It Could Mean For Biotech

So, now it starts.

This just out from ZeroHedge, linked here, shows the ‘elephant’ has begun to go mainstream.

Another chess-move.

At least one previous post (No.1, linked here), has shown the phenomenon is not a one-off event.

Now, according to the link above, there’s an estimated 300,000 affected … and we’re just getting started.

Insiders Sell … Retail Buys

Do those at the highest levels know their customer base is about to evaporate on a world-wide basis?

While they may not know every detail, they at least know something’s up. Steven Van Metre discusses the insider selling in his latest update, linked here.

Front End Phenomenon

We’re still at the beginning stages of an event that in the opinion of this author, is going to last the lifetime of those reading this post.

‘Hyperbolic statement’ one might say.

To that, I would counter with this; when it was posted, the ‘elephant’ was hyperbolic as well.

Now? Not so much.

Keeping that long range thinking in mind also keeps one from choosing the ‘insane’ human behaviors discussed by Dan (I Allegedly) in his latest post.

So, let’s take a look at what type of insanity we have going on in the markets today.

Of course, that points us to our chief cook and bottle washer, biotech (IBB).

Biotech, IBB

When we last left our hero, savior, and protector of all that is natural immunity, the biotech discussion was on Moderna (MRNA).

The thrust higher, detailed in this post was thought to be too fast for a sustained reversal. Well, it was right and wrong at the same time.

Moderna wound up reversing … sort of.

At the same time, the biotech sector headed lower to support and is now moving higher.

The weekly IBB, chart has the support (lower blue line) and potential up-thrust location (also 50%, retrace) identified.

The zoom shows the narrow gap between the weekly bars and 50% retrace.

If price action makes it past the resistance bars and into the gap, IBB would then be in up-thrust position (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279


Panic In The Streets …

Remain Calm. All, Is Well.

All, Is Well !!!

It certainly feels like Animal House, doesn’t it?

A bunch of idiots running around, glued to the mainstream narrative.

However, let’s not digress but rather get to the chief cook and bottle washer at hand.

Moderna (MRNA) and Biotech (IBB).

Biotech: MRNA, IBB

Moderna’s move above resistance (‘Target’ level in this update) seems too fast for up-thrust and reversal.

It could reverse from here.

However, the more likely scenario is the mainstream milks this whole thing all the way to Christmas and beyond.

That brings us to the sector itself, IBB:

We’ll go straight to the marked-up (daily) chart.

It’s starting to look familiar isn’t it?

Spring-to-Up-Thrust … Spring-to-Up-Thrust

But wait … there’s more!

A Fibonacci 21-Days from the most recent IBB, low on November 23rd, puts the date at December 22; The Winter Solstice.

How convenient.

Of course, anything can happen between now and then. At least we have a potential target and scenario.

As with the gold miner’s (GDX) short that’s still on-going (not advice, not a recommendation), we get to see how it all plays out.

Will Biotech, IBB, be in up-thrust (reversal) position, on or around December 22nd?

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

… Cue The ‘Hype’

Right On Schedule … A New ‘Variant’

Seems like just yesterday, we were saying:

“There’s all kinds of nastiness in the guise of ‘new strains’ out there; likely to raise their heads before Christmas and probably after as well.”

Wait, … that really was, yesterday.

So, now we have the ‘Nu variant’.

Get it? A, new variant. 🙂

The ‘Epsilon’ variant (from the idiot in Brave New World) is probably being saved for last … because if anyone’s still believing the hype by that time, it won’t matter … they’ll be fully ‘boosted’.

That doesn’t mean the pros can’t make money off the herd … while there still is a herd.

Which brings us to today’s underside test action of MRNA.

Moderna (MRNA):

Well, that retrace was quick.

First, let’s show yesterday’s weekly chart.

And now, today’s

It’s true that price action is testing the underside.

However, if we go to the daily chart (below), we can see if price action can make it just a bit higher … to the 360 – 380 area, then we have an up-thrust (potential reversal) condition.

The chart looks similar to our gold (GLD) up-thrust target, linked here for reference.

Recall, for that set-up, it took two months for GLD, to penetrate resistance … and then go into a vicious reversal.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Tech Talk, Moderna (MRNA)

Underside Test

Even though scenes like this one, this one and this one, are now common, the mainstream still seems to be ‘mystified’ as to the cause.

With all that happening as we speak, Moderna (MRNA) is finding itself potentially rising to test the underside of its trend line break.

Moderna (MRNA):

Weekly un-marked chart

Marked up with trendline break

Zoom in, of potential underside test area.

Summary:

Markets like to test … it’s what they do.

Sometimes, as with the gold hysteria, there’s a story to go along with the action. All intended to herd the easily led into the wrong side of the trade.

So, it could be with MRNA.

There’s all kinds of nastiness in the guise of ‘new strains’ out there; likely to raise their heads before Christmas and probably after as well.

These events may coincide with the previous post about biotech possibly heading for retrace and up-thrust.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Oil: Froth At The Top

XOP Down, XOM Up

Oil sector proxy XOP, posted outside-down (key reversal) while Exxon (XOM) closed higher.

If we’re in the middle of a reversal, this is normal.

Parts of the sector are already heading lower while typically, the larger caps are the last to complete the change.

This interview with Carter Worth, even though it’s short at only two-minutes thirty seconds, paints not-so-good picture.

He says in a typical scenario that’s repeated twice since the late April ’20 lows, oil has declined by 16% – 20%.

When asked how the equities would do, he hesitates, then says ‘It’s not worth the risk [to be long]’.

It’s a polite way to say they’re likely to get whacked.

Moderna (MRNA)

By now, everybody’s heard the news on Moderna.

Trouble for Moderna was spotted a while back and discussed in this post … along with a prediction that class-action may be forthcoming.

Our stopwatch is still ticking.

Positions

The account positions are short Oil & Gas XOP, using DUG as the vehicle (not advice, not a recommendation).

So far, its been a lot of banging around without much progress either way. However, at this point, a new low for DUG, below today’s low would signal trouble for the short side.

Stay Tuned

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Moderna (injections) Suspended

Biotech, Bricks In The Wall

Complete Implosion.

This site’s been steadfast for over a year; biotech above all others, has the highest chance of sustained, long-term collapse.

‘Collapse’ is an overused word these days. It may have lost some meaning.

How about the word ‘exposure‘?

Biotech has the highest chance of being exposed (not advice, not a recommendation).

Sweden Suspends Moderna:

There it is out in the mainstream: Indefinite suspension.

About a week ago, the fist bullet item in this list discussed Moderna; that when price action reverses to the down-side (after being a market darling), the lawsuits start.

It’s not the lawsuits themselves, but the discovery process that’s part of the trial … if it goes to trial.

One can guess with some assurance, the last thing Moderna wants is for this baby (any potential lawsuit) to go to discovery and trial.

This could be one of those times, popcorn is justified; watching it all from the sidelines.

Southwest Backs Off:

Looks like greed is more powerful than jabs.

At least we can see the priorities and keep that for future reference.

Now, all-of-a-sudden, it makes no sense to destroy executive stock options with forced collapse of the organization.

Glad we have such genius executives in charge. 🙂

Meanwhile, Back At The Ranch:

While all that’s going on, we still have the financial press talking about earnings and sales and ‘pent up demand’ like any of that is important or actually real.

The only reality at this point in time, is the price.

Biotech SPBIO, Inverse Fund LABD Analysis:

We’re going to start with the un-marked chart of SPBIO:

Next, we’re going to invert that chart; giving a better perspective of what the inverse fund LABD, is tracking:

Repeating a previous observation; price action over the last two months (from late August to now), has calmed down.

Price range has narrowed and movement looks orderly.

Our take on this; bears have assumed control and are preparing (opening positions) for a directional move.

Compared to my firm and probably anyone reading, their capital is unlimited. They’re also patient.

Depending on the level of greed, they’re keeping price action from a major breakout until positioning is complete (not advice, not a recommendation).

Wyckoff termed this phenomenon (a century ago) as the ‘composite operator’, or the ‘central mind’.

This is how markets work. There’s no getting away from it.

By making a transaction, any transaction, one has implicitly entered the ‘arena’ where the gladiators (the professionals) are ready to take all you own.

Moving in a little closer, we already have a trend.

Price action bounced off support on Friday (resistance on the inverted chart) but closed nearly unchanged.

Summary:

When you have satire like this and especially at time stamp 6:35, the pressure continues to build … almost from all sides.

My firm remains short SPBIO via LABD (not advice, not a recommendation).

That is, until the market itself says the bearish analysis is wrong or it’s time to exit.

Stay Tuned

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Random Notes

The Usual Suspects For The Week

No. 1

Moderna: Bad News On The Way?

Whenever a high-flyer darling stock changes course and reverses down in a big way, the lawsuits start.

‘Investors’ only know one direction … up.

They figure they’re so smart, any decision from them that does not work out, must be someone else’s fault.

Class Action for Moderna (with discovery) may be dead ahead.

MRNA is currently down – 34.8%, from its all time highs.

Let’s start our stopwatch and see how long it takes for the first ‘Notice’.

No. 2

‘How To Short The Dollar’

Well, if you need to know how to do it, you shouldn’t be doing it.

No. 3

Gold Pontifications

You don’t have to go more than 1:18, into this interview to get an inaccurate definition of inflation.

With that said, it does not keep the (delusional) bugs in the comment section from eating it up.

The interviewer, if he had the strength, could have stopped it right there and challenged with: ‘Inflation is defined as the expansion of credit that results in increased demand that in turn results in higher prices.’

At this point in time, we’re in credit destruction (i.e. Wells Fargo shutting down credit lines) not expansion … um, which is deflation not inflation.

Look at the velocity of money; enough said.

Moving on, there’s possible miss-direction at time stamp 11:40.

Anyone talking about that subject as something that’s real (other than this type of real) is at best, disingenuous.

What’s in the media is there for a reason.

That reason is to shape your thoughts and keep you thinking ‘inside the box‘.

Ending this item on a humorous note, years ago, probably 2003 – 2004, I had signed up for several Dr. Elder webinars.

During one of those, he made an off-hand comment to the effect:

‘Never trust a bald man who wears a hat indoors

Not kidding.

His son, who was the moderator at the time, immediately went into damage control; posting apologies directly into the live stream 🙂

No. 4

Lions and Tigers and Bears … Oh My!

Now we need to inject zoo animals.

You can’t make this stuff up.

Who knows when or if the tide will turn.

At this point, it looks like there will be complete destruction first which brings us to the next bullet item.

No. 5

Only Problems. No Solutions

Personal Anecdote. Skip to No. 6, if not interested.

Back in the day as an Engineering Manager, there were times an employee (usually an engineer) would walk into my office and give me a list of problems on a particular project.

If this happened a second time, I would sort of gently (maybe) let them know, ‘If you bring me problems, you need to have solutions as well.’

I also let them know, if they were not able to come with solutions, I would map out a long-term action plan (basically starting documentation for termination) for their continued development.

How many YouTube sites talk endlessly about the problem?

It does not take much effort or thought or creativeness to tell us what we already know.

This site not only presents the problem(s), but also presents potential solution(s) or action(s).

Example:

Problem: Markets stretched to valuations beyond historical extremes. Traditional methods of analysis (P/E ratios, Book Value. etc.) no longer work. The market could ‘disconnect’ and be unavailable to trade for days or weeks at a time (think Klaus Schwab ‘cyber attack’).

Solution: (not advice, not a recommendation):

Identify a market and trading vehicle that has its own direction and is separated from the overall mass-hysteria. Position ‘in and out’, as required in that market until such time there are other opportunities of similar potential.

That market thus far, has been identified as biotech, SPBIO. The trading vehicle is LABD (not advice, not a recommendation).

Any disconnect or surprise event is already factored in as a likely positive for the position taken, i.e. being short biotech

We’re not only taking this approach for the current market environment but the supply chain as well.

The supply chain shut down and the potential famine that will ensue, is one of, if not the main reason(s) silver and gold may be of no use (at least temporarily) in the troubles to come.

They shall cast their silver in the streets, and their gold shall be removed: their silver and their gold shall not be able to deliver them in the day of the wrath of the LORD:

At this point in time, I’m sticking with Ezekiel.

No. 6

Mr E Is Back

Back in the day, before YouTube did its purge, we had Mr. E.

Evidently he was verbally abused in an elevator by a hoard of the mindless and masked.

This video is his response.

No. 7

Taboo, Scaboo

Well, it would not be a compete ‘Notes’ update without mention of Scaboo.

Here he is at his new home … a few miles north of town.

As mentioned in the last update, the hen that gave him trouble at the outset, well, he’s got that all sorted out.

According to his new owners, he takes his job seriously.

He protects the hens and is meticulous about getting them into their coop at night. He then goes to his own coop; sort of a personal man-cave.

This picture was taken by the new owner.

You have to figure they must be pleased with him to wait long enough to capture such a majestic pose.

Stay Tuned

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Moderna Djab, Investigated

Before The Open

But Don’t Expect Anything

Round up the usual suspects.

Make it look like we’re doing something.

Our ‘parabolic’ report on MRNA, was posted before the open, August 10th.

That post included the following summary:

‘This is the type of parabolic rise (and blow-off top) typically seen in commodities.’

Then, about seven minutes after the open, MRNA peaked and reversed into a two-day collapse over -25%.

Down-thrust energy, the amount of downward force in price action, was literally off the chart; the strongest ever recorded since MRNA, started trading in December of 2018.

Price action leads the news. This case was no exception.

This report, just out on ZeroHedge shows there’s a half-hearted attempt to draw attention to a so-called ‘rare’ side effect.

Even so, the insiders probably figure the jig is up and they’re bailing out.

The biotech sector (SPBIO) continues its bear market decline. Yesterday, it closed down over -32%, from its February 2021, highs.

Looking at MRNA, we see a now familiar set-up:

‘Spring to Up-thrust’

A casual look at MRNA, and you can see shades of 1929, in the price action.

We’ve had the ‘crash’, the 25% decline followed by a weak rebound.

Now, there may be a sustained and long term decline (months, years) ultimately bringing MRNA, below its all-time trading lows (below 11.54).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Moderna, goes Parabolic

8:07 a.m, EST

Trending @ 5,000,000 %, Annualized !!!

The MRNA daily chart shows price action trending higher at roughly 5-million percent on annualized basis.

This is the type of parabolic rise (and blow-off top) typically seen in commodities.

Obviously, you can’t keep 5-million percent going for long.

Moderna has now taken over Amgen (AMGN) as the largest cap in the IBB, biotech (ETF) index.

Amgen’s been trading since June 17, 1983. Moderna started just a little over two and a half years ago.

But let’s take a look at what’s really happening … what’s really going on behind the apparent good fortune of MRNA.

At one hour 22-miuntes and change, this link provides the most succinct account (to date) of the situation at hand.

Names, dates, places, patent numbers … it’s all there.

Pre-market trading in MRNA, shows a flat to slightly higher open.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.